Semaglutide (Wegovy®)
Clinical Indication
Weight management in overweight and obese adults
Comments
Work is ongoing locally to plan for the implementation of NICE TA875. Semaglutide will only be available to patients that meet the eligibility criteria outlined by NICE and only through a specialist weight management service.
Date of classification
June 2023
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.